SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

ZW191

ZYME·Zymeworks Inc.
MIXED
Drug Impact Rating4/10
Trial phase
Phase 1
Time to market
ZW191 is in Phase 1 with no registrational trial design announced. Assuming successful Phase 1 completion, a Phase 2/3 registrational trial would likely start in 2027, putting a potential FDA submission several years away, likely 2029 or later.
Why 4/10
No hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for ZW191 in the next ~12 months. The drug is in Phase 1 with no announced registrational trial start date. ZW191 is one of several pipeline assets at a multi-asset company that also has an approved drug (Ziihera), royalty streams, and a Roche partnership, so even a Phase 2 start would not be a single-asset binary event.
Actionable Insight MIXED

The next catalyst for ZW191 is likely updated Phase 1 data at a medical conference in 2027 or news of Phase 2/registrational trial initiation. Zymeworks reports Q4 2026 earnings in early 2027, which may include a pipeline update. The strong ESMO 2026 response rate (64.5%) supports advancement, but the drug remains early-stage with no hard binary catalyst on the calendar.

Price Chart

Loading chart...

Executive Summary

ZW191 is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRalpha), being developed by Zymeworks Inc. (NASDAQ: ZYME) primarily for platinum-resistant ovarian cancer. It is currently in Phase 1 clinical testing, with the first patient dosed in November 2024. The drug has shown promising early efficacy data: a confirmed objective response rate of 64.5% at the 6.4 mg/kg dose in heavily pretreated patients at ESMO 2026, and a 61% response rate with median progression-free survival of 7.6 months at AACR 2026. The FDA granted Fast Track designation in March 2026. ZW191 faces competition from AbbVie's already-approved Elahere (mirvetuximab soravtansine) but differentiates via a novel topoisomerase I inhibitor payload and activity across all FRalpha expression levels. Zymeworks is a multi-asset company with an approved drug (Ziihera), royalty streams, and a Roche collaboration, so ZW191 is one of several value drivers rather than a single-asset binary.

How It Works

ZW191 is an antibody-drug conjugate (ADC), a type of targeted cancer therapy that works like a guided missile. One part of the drug (the antibody) seeks out and binds to a protein called folate receptor alpha (FRalpha) that is found on the surface of many ovarian, endometrial and lung cancer cells. Once attached, the drug delivers a potent chemotherapy payload (a topoisomerase I inhibitor called ZD06519) directly inside the cancer cell, killing it while largely sparing healthy cells. The drug is designed with a high drug-to-antibody ratio, meaning each antibody carries multiple payload molecules for a stronger kill effect.

Trial Status

ZW191 is in an ongoing Phase 1 trial (first patient dosed November 2024) evaluating it in FRalpha-expressing advanced solid tumors including ovarian, endometrial, and non-small cell lung cancer. The dose-escalation portion was completed and presented at AACR 2026. A randomized dose-optimization portion was presented at ESMO Congress 2026, showing a 64.5% confirmed objective response rate at the 6.4 mg/kg dose in platinum-resistant ovarian cancer. The company has not yet announced a Phase 2 or registrational trial start date.

The Two-Sided Case

▲ Bull Case5
ZW191 showed a confirmed objective response rate of 64.5% at the 6.4 mg/kg dose in heavily pretreated platinum-resistant ovarian cancer patients at ESMO 2026, a compelling efficacy signal for an early-phase trial.
The drug demonstrated activity across all FRα expression levels, potentially broadening the addressable patient population versus Elahere, which is restricted to high FRα expressers.
ZW191 uses a proprietary topoisomerase I inhibitor payload (ZD06519) with a high drug-to-antibody ratio, a differentiated mechanism from Elahere's maytansinoid payload.
FDA granted Fast Track designation in March 2026, which can accelerate development and regulatory review.
Zymeworks has a strong balance sheet (over $400M in liquid assets per a May 2026 Seeking Alpha report) and recently raised 2026 revenue guidance to $337M-$351M, providing ample funding to advance ZW191 without near-term dilution risk.
▼ Bear Case5
ZW191 is still in Phase 1, years from potential approval, with no registrational trial design or start date announced as of November 2026.
The FRα-targeted ADC space has a formidable competitor: AbbVie's Elahere (mirvetuximab soravtansine) is already FDA-approved for FRα-positive platinum-resistant ovarian cancer, creating a high bar for differentiation.
Phase 1 data are from a small, non-randomized sample; response rates often shrink in larger, more rigorous trials.
Zymeworks saw net institutional trimming in Q2/Q3 2026 from several large holders including Deutsche Bank, FMR, and Citigroup, suggesting mixed conviction on the broader story.
An insider (EVP of R&D) sold ~$358K worth of shares in October 2026.

Upcoming Catalysts

  • Updated Phase 1 data at a medical conference in 2027 (e.g., ASCO, ESMO, SGO)
  • Announcement of Phase 2 or registrational trial design and initiation
  • Potential partnership or licensing deal for ZW191 given Zymeworks' partnering-focused strategy

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Zymeworks Inc. PRESS-RELEASE ZYME ·Originating report

Sources · 9

Hover a chip for the title
1 morningstar.com2 marketwatch.com3 markets.financialcontent.com4 fox8.com5 seekingalpha.com6 markets.businessinsider.com7 cancernetwork.com8 markets.financialcontent.com9 streetinsider.com